Komori
Eisai (4523) · InitiativeFirst stated

Approval of changes to the dosage and administration of Aricept for dementia with Lewy bodies

First written in FY2023-Q3. . Latest entry: FY2023-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Approval of a Change to Aricept's Dosage and Administration for Dementia with Lewy BodiesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023-Q3First statedAnnual report

    「2022年11月、日本において、アルツハイマー型認知症・レビー小体型認知症治療剤「アリセプト」（一般名：ドネペジル塩酸塩）について、レビー小体型認知症に係る再審査結果を受けて、用法・用量に関する承認事項の一部変更を申請し、承認されました。なお、レビー小体型認知症に係る効能・効果については変更ありません。」

    アリセプトについて、レビー小体型認知症に係る再審査結果を受け、用法・用量の承認事項を一部変更し承認を取得した。効能・効果自体は変更していない。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Eisai yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Approval of changes to the dosage and administration of Aricept for dementia with Lewy bodies | Eisai Co.,Ltd. (4523) | Komori